Studies find monoclonal antibodies and remdesivir effective, while vaccine-associated myocarditis is rare
A trial of casirivimab plus imdevimab indicated it reduced risk of hospitalization or death, the CDC urged vaccination during pregnancy and updated its v-safe tool, and an analysis showed that postvaccine myocarditis occurred in men and resolved with conservative treatment.
5 Oct 2021
Third shot for immunocompromised patients, ACP and others urge vaccine in pregnancy, more COVID-19 news
The FDA and multiple new studies supported a third vaccine dose for organ transplant patients, an ACP statement and an observational trial highlighted benefits of vaccination during pregnancy, and a randomized trial found benefit from budesonide in high-risk outpatients with COVID-19.
17 Aug 2021
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
15 Jun 2021
George M. Abraham, MD, MPH, MACP, ACP's President, recently discussed the difference between third shots and boosters and other complexities of vaccination, as well as offered advice to internists on getting more patients vaccinated.
23 Nov 2021
New studies looked at the safety of the adenovirus COVID-19 vaccines, the effectiveness of almost all the vaccines, and the impacts of COVID-19 infection in pregnancy and on long-term cardiac function. A physician columnist addressed pandemic-related anger.
11 May 2021
Antibodies persisted six months after vaccination, and a graded dosing protocol allowed patients with reactions to a first shot to get a second. Surveyed Americans wanted to prioritize front-line workers and those with chronic conditions for vaccination, and a columnist finds reasons for hope.
13 Apr 2021
Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
31 Aug 2021
Several COVID-19 studies looked at persistent symptoms, while new vaccine research found limited antibody responses in some patients and advised on tests for clotting complications. Other studies quantified the target population for tocilizumab treatment and gender differences in infections.
25 May 2021
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
2 Mar 2021
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
20 Jul 2021